SARS-COV-2 vaccination after stem cell transplantation for scleroderma

Ann Rheum Dis. 2021 Oct;80(10):1354-1355. doi: 10.1136/annrheumdis-2021-220677. Epub 2021 May 28.

Authors

Doron Rimar¹, Gleb Slobodin², Alona Paz³, Israel Henig⁴, Tsila Zuckerman⁴

Affiliations

¹ Rheumatology, Bnai Zion Medical Centre, Haifa, Israel doronrimar@gmail.com.
² Rheumatology, Bnai Zion Medical Centre, Haifa, Israel.
³ Infectious Diseases Unit, Bnai Zion Medical Centre, Haifa, Israel.
⁴ Department of Hematology and Bone Marrow Transplantation, Rambam medical center, Haifa, Israel.

PMID: 34049853
DOI: 10.1136/annrheumdis-2021-220677

No abstract available

Keywords: COVID-19; systemic sclerosis; vaccination.

Publication types

Letter

MeSH terms

Adult
Aged
Antibodies, Viral / blood
Antibodies, Viral / immunology
BNT162 Vaccine
CD4-Positive T-Lymphocytes / immunology
COVID-19 / prevention & control*
COVID-19 Vaccines / immunology*
Female
Hematopoietic Stem Cell Transplantation
Humans
Immunocompromised Host / immunology*
Male
Middle Aged
SARS-CoV-2
Scleroderma, Systemic / immunology*
Scleroderma, Systemic / therapy

Substances

Antibodies, Viral
COVID-19 Vaccines
BNT162 Vaccine